Use of remdesivir for COVID-19 in patients with hematologic cancer.

Alexandra Martin-OnraëtCorazón Barrientos-FloresDiana Vilar Compte Carolina Pérez-Jimenez Pamela Alatorre-Fernandez

Published in: Clinical and experimental medicine (2022)

Patients with HM and COVID-19 continue to present with high risk of complications. More prospective studies are needed to define the impact of antivirals in this high-risk group, including the best duration of treatment. Also, better vaccine coverage and access to treatment are mandatory.

Keyphrases

coronavirus disease
sars cov
squamous cell carcinoma
papillary thyroid
risk factors
young adults
replacement therapy
case control
affordable care act